Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.36 |
| ▸ | ESR1 | P03372 | 8/20 | 0.36 |
| ▸ | NOS1 | P29475 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24285781 | 0.84 | IDO1 (0.34) | IDO1AXLESR2ESR1NOS1 | |
| SCHEMBL17030759 | 0.84 | IDO1 (0.41) | IDO1AXLESR2ESR1NOS1 | |
| SCHEMBL25794205 | 0.80 | IDO1 (0.40) | IDO1CDK2FLT3CCNA1METAP2 | |
| SCHEMBL18456308 | 0.79 | AXL (0.50) | IDO1AXLESR2ESR1NOS1 | |
| SCHEMBL25799613 | 0.79 | NOS1 (0.39) | IDO1AXLESR2ESR1NOS1 | |
| SCHEMBL18408609 | 0.76 | — | — | |
| SCHEMBL19115364 | 0.75 | MAPT (0.51) | NOS1FLT3TRPA1 | |
| SCHEMBL24089316 | 0.75 | — | — | |
| SCHEMBL10285272 | 0.75 | AXL (0.62) | IDO1AXLNOS1CDK2TRPA1 | |
| SCHEMBL20850537 | 0.74 | CDK2 (0.43) | IDO1AXLESR2ESR1NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230002345-A1 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-05 | — | — | US | disclosed |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | ARAXES PHARMA LLC (US) | 2022-03-22 | — | — | US | disclosed |
| US-11136308-B2 | Substituted quinazoline and quinazolinone compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200109153-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | ASTRAZENECA AB (SE) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217982-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | IDO1 4657/4885AXL 2161/4885ESR2 2461/4885 |
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | IDO1 4845/4885AXL 3362/4885ESR2 335/4885 |
| US-20200109153-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | KRAS, NRAS, HRAS | IDO1 4682/4885AXL 2710/4885ESR2 2214/4885 |
| US-20230002345-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | IDO1 4845/4885AXL 3362/4885ESR2 335/4885 |
| US-11136308-B2 | Substituted quinazoline and quinazolinone compounds and methods of use thereof | KRAS, NRAS, HRAS | IDO1 3777/4885AXL 2399/4885ESR2 2196/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | IDO1 3814/4885AXL 2581/4885ESR2 4674/4885 |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | KRAS, NRAS, HRAS | IDO1 1513/4885AXL 3576/4885ESR2 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.